Peptide Knowledge Base · GH-axis
Ipamorelin: what it is, what the evidence says, and its real status
A selective growth-hormone secretagogue, the usual partner to CJC-1295, also non-compoundable in the US.
Short version: CJC-1295's usual partner, and under the same FDA Category 2 restriction, non-compoundable. Education only; the legal GH-axis answer is Sermorelin.
Can you actually get it?
Plain-English verdict: Education only.
Regulatory status: FDA Category 2 (non-compoundable) · Education only.
Not available. Like CJC-1295, Ipamorelin sits on FDA compounding Category 2 (non-compoundable since 2023). We educate only and route you to the legal GH-axis option, Sermorelin.
How does Ipamorelin work?
A selective ghrelin-receptor agonist (GH secretagogue) that prompts pituitary GH release with relatively little effect on cortisol or prolactin.
What it does — and what it does not do
What it does: Studied as a selective GH secretagogue for recovery and sleep interest.
What it does not do: It is non-compoundable in the US and is not offered by Peptós.LIFE, education only.
How honest is the evidence?
Evidence grade C — selective GH secretagogue; human outcome data limited. Read our grading methodology for what each grade means.
What we still don't know: Human outcome data is limited; long-term effects are uncharacterized.
WADA status: Banned (S2).
How it is taken
Not offered; education only.
Who should not take it
WADA S2 banned; non-compoundable. Not a substitute for clinical GH evaluation.
Sources
GH-secretagogue clinical literature · FDA compounding Category 2 list
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.